Hanmi
Pharmaceuticals Co., Ltd. today announced that it has entered into an
exclusive license, agreement with Janssen Pharmaceuticals, Inc.
JNJ, for the development and commercialization of
oxyntomodulin-based therapies including Hanmi's HM12525A (LAPSGLP/GCG),
a novel biologic GLP-1/Glucagon dual receptor agonist to treat diabetes
and obesity, which is expected to enter Phase 2 studies next year.
HM12525A is an oxyntomodulin-based therapy (GLP-1/glucagon receptor dual
agonist) that has shown evidence of improving multiple metabolic
parameters that lead to improved blood glucose, body weight, and insulin
sensitivity. This asset has the potential, as a once weekly therapy, to
be a best-in-class oxyntomodulin-based therapy.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in